PHOENIX PHARMACOLOGICS, INC.

Company Information

Company Name
PHOENIX PHARMACOLOGICS, INC.
Address
PHOENIX PHARMACOLOGICS, INC.
ASTECC FACILITY #A-217
LEXINGTON, KY, 40506
Phone
1 859-257-9027
URL
n/a
DUNS
n/a
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$300,454.00
5
SBIR Phase II
$1,192,428.00
2
Chart code to be here

Award List

  1. ARGININE DEIMINASE AS AN ANTI-CANCER THERAPY

    Amount: $100,492.00

    Not Available A novel high temperature inductive turbine blade tip clearance sensor is proposed to meet the needs indicated by the Air Force and corroborated by several turbine manufacturers for rese ...

    SBIR Phase I 1999 Department of Health and Human Services
  2. Arginine deiminase as an Anti-Cancer Therapy

    Amount: $0.00

    DESCRIPTION: The distinctive arginine requirement of hepatocellular carcinomas and malignant melanomas provides the basis for a new potential chemotherapy. Just as acute lymphocytic leuk ...

    SBIR Phase I 2001 Department of Health and Human Services
  3. Arginine deiminase as an Anti-Cancer Therapy

    Amount: $383,600.00

    DESCRIPTION: The distinctive arginine requirement of hepatocellular carcinomas and malignant melanomas provides the basis for a new potential chemotherapy. Just as acute lymphocytic leuk ...

    SBIR Phase II 2001 Department of Health and Human Services
  4. MODIFIED TNF-ALPHA: AN ANTI CANCER THERAPY

    Amount: $99,962.00

    DESCRIPTION (PROVIDED BY APPLICANT): The long-term goal of the proposed research is the development of effective anti-cancer agents, modified human tumor necrosis factor-alphas ( ...

    SBIR Phase I 2001 Department of Health and Human Services
  5. PRECLINICAL DEVELOPMENT OF URICASE-PEG 20

    Amount: $100,000.00

    Hyperuricemia (elevated serum uric acid) results in gouty arthritis and chronic renal disease. Severe hyperuricemia can occur following cancer chemotherapy (tumor lysis syndrome) and organ transplanta ...

    SBIR Phase I 2002 Department of Health and Human Services
  6. Preclinical Development of PEG-TNF

    Amount: $808,828.00

    DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemi ...

    SBIR Phase II 2004 Department of Health and Human Services
  7. Preclinical Development of PEG-TNF

    Amount: $0.00

    DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemi ...

    SBIR Phase I 2004 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government